Related Experiment Video
Updated: Oct 13, 2025
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Apnoea of Prematurity and Neurodevelopmental Outcomes: Current Understanding and Future Prospects for Research
Max Williamson1, Ravi Poorun2, Caroline Hartley1
1Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Insights
Apnoea of prematurity in infants can lead to poor neurodevelopmental outcomes. Caffeine therapy is crucial for reducing these risks, but further research is needed to understand the direct impact of apnoea on infant brain development.
Area of Science:
- Neonatal Medicine
- Developmental Neuroscience
- Pharmacology
Background:
- Premature infants face significant risks from apnoea, a condition linked to hypoxia and long-term neurodevelopmental issues.
- While caffeine therapy shows promise in mitigating adverse outcomes, the direct causal link between apnoea and neurodevelopmental delay remains debated.
- Understanding the precise relationship is critical for optimizing care for vulnerable preterm infants.
Purpose of the Study:
- To review the pathophysiology of apnoea of prematurity.
- To examine the association between apnoea and neurodevelopmental delay in preterm infants.
- To discuss the role of caffeine therapy and propose future research directions.
Main Methods:
- Literature review of studies on apnoea of prematurity, neurodevelopmental outcomes, and caffeine therapy.
- Discussion of the pathophysiology of neonatal apnoea and its impact.
- Analysis of existing research to identify knowledge gaps.
Main Results:
- Apnoea of prematurity is associated with significant short-term (hypoxia) and long-term (neurodevelopmental) morbidities.
- Caffeine therapy has demonstrated efficacy in reducing the risk of adverse neurodevelopmental outcomes.
- The precise contribution of apnoea to neurodevelopmental delay, versus other prematurity sequelae, requires further investigation.
Conclusions:
- Improved methods for measuring apnoea and understanding the neonatal brain's response to hypoxia are needed.
- Developing a risk stratification system for preterm infants at risk of apnoea and neurodevelopmental delay is essential.
- Tailored caffeine treatment strategies can optimize neonatal care and improve long-term outcomes for preterm infants.
Abstract:
Infants who are born prematurely are at significant risk of apnoea. In addition to the short-term consequences such as hypoxia, apnoea of prematurity has been associated with long-term morbidity, including poor neurodevelopmental outcomes. Clinical trials have illustrated the importance of methylxanthine drugs, in particular caffeine, in reducing the risk of long term adverse neurodevelopmental outcomes. However, the extent to which apnoea is causative of this secondary neurodevelopmental delay or is just associated in a background of other sequelae of prematurity remains unclear. In this review, we first discuss the pathophysiology of apnoea of prematurity, previous studies investigating the relationship between apnoea and neurodevelopmental delay, and treatment of apnoea with caffeine therapy. We propose a need for better methods of measuring apnoea, along with improved understanding of the neonatal brain's response to consequent hypoxia. Only then can we start to disentangle the effects of apnoea on neurodevelopment in preterm infants. Moreover, by better identifying those infants who are at risk of apnoea, and neurodevelopmental delay, we can work toward a risk stratification system for these infants that is clinically actionable, for example, with doses of caffeine tailored to the individual. Optimising treatment of apnoea for individual infants will improve neonatal care and long-term outcomes for this population.
Related Concept Videos
01:30Neurulation
01:21The Nativist Approach